Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 34095496 | HLA-DQA1*02 | NA | Chinese | rs3129731 | rs1071817 | unclassified | |
| NA | |||||||
| 34095496 | HLA-B (HLA-B) | NA | Chinese | rs3129731 | rs1071817 | unclassified | |
| NA | |||||||
| 6610228 | HLA-A (HLA-A) | postpartum thyroiditis | Danish | NA | NA | unclassified | |
| thirteen danish women with postpartum thyroiditis were hla-a, b, c and -dr typed. | |||||||
| 6610228 | HLA-DR (HLA-DR) | postpartum thyroiditis | Danish | NA | NA | unclassified | |
| thirteen danish women with postpartum thyroiditis were hla-a, b, c and -dr typed. | |||||||
| 8640296 | NA (NA) | postpartum thyroiditis | NA | NA | NA | unclassified | |
| the objective was to re-evaluate the association between class ii hla-dr and dq miic antigens and postpartum thyroiditis (ppt) and to determine the prevalence of the class iii complement allotypes of properdin factor b (bf), c4a and c4b in this condition. | |||||||
| 8640296 | HLA-DR (HLA-DR) | postpartum thyroiditis | NA | NA | NA | unclassified | |
| the objective was to re-evaluate the association between class ii hla-dr and dq miic antigens and postpartum thyroiditis (ppt) and to determine the prevalence of the class iii complement allotypes of properdin factor b (bf), c4a and c4b in this condition. | |||||||
| 3491715 | HLA-DR (HLA-DR) | fibromyalgia | NA | NA | NA | unclassified | |
| hla antigen class i (a, b, c) and ii (dr) were determined in a small group of fibrositis (fibromyalgia) patients and normal controls. | |||||||
| 3491715 | HLA-DRB1*04 | fibrositis | NA | NA | NA | unclassified | |
| sixty-seven percent of fibrositis patients had dr4 versus 30% of normal controls. | |||||||
| 7480270 | HLA (HLA) | fibromyalgia | NA | NA | NA | only_studied | |
| one-hundred and ninety-nine subjects were evaluated by hla typing: symptomatic patients with implants (group i, n = 77), asymptomatic women with implants (group ii, n = 37), healthy female volunteers without implants (group iii, n = 54), and fibromyalgia patients without implants (group iv, n = 31). | |||||||
| 7480270 | HLA-DR53 (BROAD ANTIGEN) | fibromyalgia | NA | NA | NA | unclassified | |
| the fibromyalgia patients were strikingly similar to group i women in terms of hla-dr molecules, with 65 percent of group iv being positive for dr53. | |||||||
Copyright 2024